Failure to up-regulate VEGF165b in maternal plasma is a first trimester predictive marker for pre-eclampsia

Clinical Science

Volumn 116, Issue 3, 2009, Pages 265-272

  Bills, Victoria L ^a   Varet, Julia ^b   Millar, Ann ^b   Harper, Steven J ^a   Soothill, Peter W ^a   Bates, David O ^a  

^a UNIVERSITY OF BRISTOL   (United Kingdom)

^b SOUTHMEAD HOSPITAL   (United Kingdom)

Author keywords

Angiogenesis; Plasma marker; Pre eclampsia; Splice variant; Vascular endothelial growth factor165b (VEGF165b) vascular permeability

Indexed keywords

ENDOGLIN; VASCULOTROPIN 165; VASCULOTROPIN RECEPTOR 1; BIOLOGICAL MARKER; CELL SURFACE RECEPTOR; ENG PROTEIN, HUMAN; IL1RL1 PROTEIN, HUMAN; LEUKOCYTE ANTIGEN; PLACENTA PROTEIN; VASCULOTROPIN A; VEGFA PROTEIN, HUMAN;

ADOLESCENT; ADULT; ARTICLE; BLOOD PRESSURE; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC ACCURACY; DIAGNOSTIC VALUE; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FIRST TRIMESTER PREGNANCY; GESTATION PERIOD; HUMAN; MATERNAL PLASMA; PREDICTION; PREECLAMPSIA; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RISK ASSESSMENT; SENSITIVITY AND SPECIFICITY; UPREGULATION; BLOOD; GESTATIONAL AGE; MATERNAL AGE; METHODOLOGY; PREGNANCY; PROGNOSIS;

ADULT; ANTIGENS, CD; BIOLOGICAL MARKERS; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; GESTATIONAL AGE; HUMANS; MATERNAL AGE; PRE-ECLAMPSIA; PREGNANCY; PREGNANCY PROTEINS; PROGNOSIS; RECEPTORS, CELL SURFACE; UP-REGULATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 60549093223     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/CS20080270     Document Type: Article

References (33)

1. Khan, K. S., Wojdyla, D., Say, L., Gülmezoglu, A. M. and Van Look, P. F. (2006) WHO analysis of causes of maternal death: a systematic review. Lancet 367, 1066-1074
2. Zhou, Y., Damsky, C. H. and Fisher, S. J. (1997) Preeclampsia is associated with failure of human cytotrophoblasts to mimic a vascular adhesion phenotype. One cause of defective endovascular invasion in this syndrome? J. Clin. Invest. 99, 2152-2164
3. Maynard, S. E., Venkatesha, S., Thadhani, R. and Karumanchi, S. A. (2005) Soluble Fms-like tyrosine kinase 1 and endothelial dysfunction in the pathogenesis of preeclampsia. Pediatr. Res. 57, 1R-7R
4. Levine, R. J., Maynard, S. E., Qian, C. et al. (2004) Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350, 672-683
5. Baumwell, S. and Karumanchi, S. A. (2007) Pre-eclampsia: clinical manifestations and molecular mechanisms. Nephron Clin. Pract. 106, c72-c81
6. Ferrara, N. (2004) Vascular endothelial growth factor: basic science and clinical progress. Endocr. Rev. 25, 581-611
7. Maynard, S. E., Min, J. Y., Merchan, J. et al. (2003) Excess placental soluble fms-like tyrosine kinase 1 (sFlt1) may contribute to endothelial dysfunction, hypertension, and proteinuria in preeclampsia. J. Clin. Invest. 111, 649-658
8. Livingston, J. C., Chin, R., Haddad, B., McKinney, E. T., Ahokas, R. and Sibai, B. M. (2000) Reductions of vascular endothelial growth factor and placental growth factor concentrations in severe preeclampsia. Am. J. Obstet. Gynecol. 183, 1554-1557
9. Lyall, F., Young, A., Boswell, F., Kingdom, J. C. and Greer, I. A. (1997) Placental expression of vascular endothelial growth factor in placentae from pregnancies complicated by pre-eclampsia and intrauterine growth restriction does not support placental hypoxia at delivery. Placenta 18, 269-276
10. McKeeman, G. C., Ardill, J. E., Caldwell, C. M., Hunter, A. J. and McClure, N. (2004) Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am. J. Obstet. Gynecol. 191, 1240-1246
11. Lee, E. S., Oh, M. J., Jung, J. W. et al. (2007) The levels of circulating vascular endothelial growth factor and soluble Flt-1 in pregnancies complicated by preeclampsia. J. Korean Med. Sci. 22, 94-98
12. 165b, an inhibitory splice variant of vascular endothelial growth factor, is down-regulated in renal cell carcinoma. Cancer Res. 62, 4123-4131
13. 165b transiently increases hydraulic conductivity, probably through VEGF receptor 1 in vivo. J. Physiol. 572, 243-257
14. xxxb, are down-regulated in pre-eclamptic placentae at term. Clin. Sci. 110, 575-585
15. 165b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy. Br. J. Cancer 98, 1366-1379
16. Alberry, M. and Soothill, P. W. (2007) Management of fetal growth restriction. Arch. Dis. Child. Fetal Neonatal Ed. 92, F62-F67
17. Brockelsby, J., Hayman, R., Ahmed, A., Warren, A., Johnson, I. and Baker, P. (1999) VEGF via VEGF receptor-1 (Flt-1) mimics preeclamptic plasma in inhibiting uterine blood vessel relaxation in pregnancy: implications in the pathogenesis of preeclampsia. Lab. Invest. 79, 1101-1111
18. Sgambati, E., Marini, M., Zappoli Thyrion, G. D. et al. (2004) VEGF expression in the placenta from pregnancies complicated by hypertensive disorders. Br. J. Obstet. Gynaecol. 111, 564-570
19. Li, Z., Zhang, Y., Ying Ma, J. et al. (2007) Recombinant vascular endothelial growth factor 121 attenuates hypertension and improves kidney damage in a rat model of preeclampsia, Hypertension 50, 686-692
20. Murakami, Y., Kobayashi, T., Omatsu, K. et al. (2005) Exogenous vascular endothelial growth factor can induce preeclampsia-like symptoms in pregnant mice. Semin. Thromb. Hemostasis 31, 307-313
21. Nadar, S. K., Karalis, I., Al Yemeni, E., Blann, A. D. and Lip, G. Y. (2005) Plasma markers of angiogenesis in pregnancy induced hypertension. Thromb. Haemostasis 94, 1071-1076
22. Anthony, F. W., Evans, P. W.,Wheeler, T. and Wood, P. J. (1997) Variation in detection of VEGF in maternal serum by immunoassay and the possible influence of binding proteins. Ann. Clin. Biochem. 34, 276-280
23. Levine, R. J., Lam, C., Qian, C. et al. (2006) Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N. Engl. J. Med. 355, 992-1005
24. Venkatesha, S., Toporsian, M., Lam, C. et al. (2006) Soluble endoglin contributes to the pathogenesis of preeclampsia. Nat. Med. 12, 642-649
25. Levine, R. J., Maynard, S. E., Qian, C. et al. (2004) Circulating angiogenic factors and the risk of preeclampsia. N. Engl. J. Med. 350, 672-683
26. Perrin, R. M., Konopatskaya, O., Qiu, Y., Harper, S., Bates, D. O. and Churchill, A. J. (2005) Diabetic retinopathy is associated with a switch in splicing from anti- to pro-angiogenic isoforms of vascular endothelial growth factor. Diabetologia 48, 2422-2427
27. 165b, an inhibitory vascular endothelial growth factor splice variant: mechanism of action, in vivo effect on angiogenesis and endogenous protein expression. Cancer Res. 64, 7822-7835
28. xxxb, the inhibitory isoforms of VEGF, in malignant melanoma. Br. J. Cancer 97, 223-230
29. 165b in Denys-Drash syndrome. J. Am. Soc. Nephrol. 18, 719-729
30. 165b, an endogenous C-terminal splice variant of VEGF, inhibits retinal neovascularization in mice. Mol. Vis. 12, 626-632
31. 165b inhibits human tumour growth in mice. Br. J. Cancer 98, 1250-1257
32. 165b. FASEB J. 22, 1104-1112
33. Duley, L., Henderson-Smart, D., Knight, M. and King, J. (2001) Antiplatelet drugs for prevention of pre-eclampsia and its consequences: systematic review. Br. Med. J. 322, 329-333